[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f5zThadsC-fwPqFpdv4v_jViaq9mAXQBH4ORvtcTSuaQ":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":33,"phaseBuckets":49,"rows":56},"Louisiana State University Health Sciences Center in New Orleans",[4],71,false,11,6,7632,12,42,[14,17,19,22,25,27,29,31],{"name":15,"count":16},"Dental Caries",4,{"name":18,"count":16},"Pulmonary Hypertension",{"name":20,"count":21},"Multiple Sclerosis",3,{"name":23,"count":24},"Quality of Life",2,{"name":26,"count":24},"HIV\u002FAIDS",{"name":28,"count":24},"Obesity",{"name":30,"count":24},"Hypertension",{"name":32,"count":24},"Alcohol Use Disorder",[34,39,44],{"nctId":35,"briefTitle":36,"date":37,"intervention":38},"NCT05663684","Does Topical Ophthalmic Proparacaine 0.5% Prior to Probing and Irrigation Decrease Pain?","2022-12-30","Proparacaine Hydrochloride ophthalmic solution, USP 0.5%",{"nctId":40,"briefTitle":41,"date":42,"intervention":43},"NCT05266898","Immunogenicity of Gardasil-9 HPV Vaccine in People Living With HIV","2025-12","Human papillomavirus 9-valent vaccine, recombinant",{"nctId":45,"briefTitle":46,"date":47,"intervention":48},"NCT05756764","Anti-obesity Pharmacotherapy and Inflammation","2026-01-30","Semaglutide",[50,51,52,53,54,55],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[57,85,103,132,150,179,197,215,233,251,269,287,305,332,361,379,404,430,460,478,496,514,539,570,598,616,641,669,701,727,751,777,804,830,848,873,898,923,947,971,989,1016,1034,1062,1084,1111],{"intervention":38,"totalTrials":58,"cells":59},1,{"EARLY_PHASE1":60,"PHASE1":63,"PHASE2":65,"PHASE3":67,"PHASE4":69,"NA":83},{"trials":61,"activeCount":62},[],0,{"trials":64,"activeCount":62},[],{"trials":66,"activeCount":62},[],{"trials":68,"activeCount":62},[],{"trials":70,"activeCount":58,"soonestReadout":37},[71],{"nctId":35,"briefTitle":36,"status":72,"phases":73,"primaryCompletion":37,"completion":74,"start":75,"enrollment":76,"conditions":77,"interventions":81},"RECRUITING",[54],"2023-01-31","2020-06-30",145,[78,79,80],"Epiphora","Dacryostenosis","Dacryocystitis",[38,82],"Balanced salt solution",{"trials":84,"activeCount":62},[],{"intervention":82,"totalTrials":58,"cells":86},{"EARLY_PHASE1":87,"PHASE1":89,"PHASE2":91,"PHASE3":93,"PHASE4":95,"NA":101},{"trials":88,"activeCount":62},[],{"trials":90,"activeCount":62},[],{"trials":92,"activeCount":62},[],{"trials":94,"activeCount":62},[],{"trials":96,"activeCount":58,"soonestReadout":37},[97],{"nctId":35,"briefTitle":36,"status":72,"phases":98,"primaryCompletion":37,"completion":74,"start":75,"enrollment":76,"conditions":99,"interventions":100},[54],[78,79,80],[38,82],{"trials":102,"activeCount":62},[],{"intervention":43,"totalTrials":58,"cells":104},{"EARLY_PHASE1":105,"PHASE1":107,"PHASE2":109,"PHASE3":111,"PHASE4":113,"NA":130},{"trials":106,"activeCount":62},[],{"trials":108,"activeCount":62},[],{"trials":110,"activeCount":62},[],{"trials":112,"activeCount":62},[],{"trials":114,"activeCount":58,"soonestReadout":42},[115],{"nctId":40,"briefTitle":41,"status":72,"phases":116,"primaryCompletion":42,"completion":117,"start":118,"enrollment":119,"conditions":120,"interventions":128},[54],"2026-06","2022-11-30",250,[121,122,123,124,125,126,127],"Papillomavirus Vaccines","Human Immunodeficiency Virus","Papillomavirus Infection","Serology","Cervical Intraepithelial Neoplasia","Anal Intraepithelial Neoplasia","Oral Cavity Infection",[43,129],"human papillomavirus vaccine, recombinant",{"trials":131,"activeCount":62},[],{"intervention":129,"totalTrials":58,"cells":133},{"EARLY_PHASE1":134,"PHASE1":136,"PHASE2":138,"PHASE3":140,"PHASE4":142,"NA":148},{"trials":135,"activeCount":62},[],{"trials":137,"activeCount":62},[],{"trials":139,"activeCount":62},[],{"trials":141,"activeCount":62},[],{"trials":143,"activeCount":58,"soonestReadout":42},[144],{"nctId":40,"briefTitle":41,"status":72,"phases":145,"primaryCompletion":42,"completion":117,"start":118,"enrollment":119,"conditions":146,"interventions":147},[54],[121,122,123,124,125,126,127],[43,129],{"trials":149,"activeCount":62},[],{"intervention":48,"totalTrials":58,"cells":151},{"EARLY_PHASE1":152,"PHASE1":154,"PHASE2":156,"PHASE3":158,"PHASE4":160,"NA":162},{"trials":153,"activeCount":62},[],{"trials":155,"activeCount":62},[],{"trials":157,"activeCount":62},[],{"trials":159,"activeCount":62},[],{"trials":161,"activeCount":62},[],{"trials":163,"activeCount":58,"soonestReadout":47},[164],{"nctId":45,"briefTitle":46,"status":165,"phases":166,"primaryCompletion":47,"completion":167,"start":168,"enrollment":169,"conditions":170,"interventions":171},"ACTIVE_NOT_RECRUITING",[],"2026-02-20","2023-06-01",30,[28],[48,172,173,174,175,176,177,178],"Phentermine-Topiramate combination","Phentermine","Tirzepatide","Topiramate","Diethylpropion","Naltrexone\u002FBupropion","Liraglutide",{"intervention":172,"totalTrials":58,"cells":180},{"EARLY_PHASE1":181,"PHASE1":183,"PHASE2":185,"PHASE3":187,"PHASE4":189,"NA":191},{"trials":182,"activeCount":62},[],{"trials":184,"activeCount":62},[],{"trials":186,"activeCount":62},[],{"trials":188,"activeCount":62},[],{"trials":190,"activeCount":62},[],{"trials":192,"activeCount":58,"soonestReadout":47},[193],{"nctId":45,"briefTitle":46,"status":165,"phases":194,"primaryCompletion":47,"completion":167,"start":168,"enrollment":169,"conditions":195,"interventions":196},[],[28],[48,172,173,174,175,176,177,178],{"intervention":173,"totalTrials":58,"cells":198},{"EARLY_PHASE1":199,"PHASE1":201,"PHASE2":203,"PHASE3":205,"PHASE4":207,"NA":209},{"trials":200,"activeCount":62},[],{"trials":202,"activeCount":62},[],{"trials":204,"activeCount":62},[],{"trials":206,"activeCount":62},[],{"trials":208,"activeCount":62},[],{"trials":210,"activeCount":58,"soonestReadout":47},[211],{"nctId":45,"briefTitle":46,"status":165,"phases":212,"primaryCompletion":47,"completion":167,"start":168,"enrollment":169,"conditions":213,"interventions":214},[],[28],[48,172,173,174,175,176,177,178],{"intervention":174,"totalTrials":58,"cells":216},{"EARLY_PHASE1":217,"PHASE1":219,"PHASE2":221,"PHASE3":223,"PHASE4":225,"NA":227},{"trials":218,"activeCount":62},[],{"trials":220,"activeCount":62},[],{"trials":222,"activeCount":62},[],{"trials":224,"activeCount":62},[],{"trials":226,"activeCount":62},[],{"trials":228,"activeCount":58,"soonestReadout":47},[229],{"nctId":45,"briefTitle":46,"status":165,"phases":230,"primaryCompletion":47,"completion":167,"start":168,"enrollment":169,"conditions":231,"interventions":232},[],[28],[48,172,173,174,175,176,177,178],{"intervention":175,"totalTrials":58,"cells":234},{"EARLY_PHASE1":235,"PHASE1":237,"PHASE2":239,"PHASE3":241,"PHASE4":243,"NA":245},{"trials":236,"activeCount":62},[],{"trials":238,"activeCount":62},[],{"trials":240,"activeCount":62},[],{"trials":242,"activeCount":62},[],{"trials":244,"activeCount":62},[],{"trials":246,"activeCount":58,"soonestReadout":47},[247],{"nctId":45,"briefTitle":46,"status":165,"phases":248,"primaryCompletion":47,"completion":167,"start":168,"enrollment":169,"conditions":249,"interventions":250},[],[28],[48,172,173,174,175,176,177,178],{"intervention":176,"totalTrials":58,"cells":252},{"EARLY_PHASE1":253,"PHASE1":255,"PHASE2":257,"PHASE3":259,"PHASE4":261,"NA":263},{"trials":254,"activeCount":62},[],{"trials":256,"activeCount":62},[],{"trials":258,"activeCount":62},[],{"trials":260,"activeCount":62},[],{"trials":262,"activeCount":62},[],{"trials":264,"activeCount":58,"soonestReadout":47},[265],{"nctId":45,"briefTitle":46,"status":165,"phases":266,"primaryCompletion":47,"completion":167,"start":168,"enrollment":169,"conditions":267,"interventions":268},[],[28],[48,172,173,174,175,176,177,178],{"intervention":177,"totalTrials":58,"cells":270},{"EARLY_PHASE1":271,"PHASE1":273,"PHASE2":275,"PHASE3":277,"PHASE4":279,"NA":281},{"trials":272,"activeCount":62},[],{"trials":274,"activeCount":62},[],{"trials":276,"activeCount":62},[],{"trials":278,"activeCount":62},[],{"trials":280,"activeCount":62},[],{"trials":282,"activeCount":58,"soonestReadout":47},[283],{"nctId":45,"briefTitle":46,"status":165,"phases":284,"primaryCompletion":47,"completion":167,"start":168,"enrollment":169,"conditions":285,"interventions":286},[],[28],[48,172,173,174,175,176,177,178],{"intervention":178,"totalTrials":58,"cells":288},{"EARLY_PHASE1":289,"PHASE1":291,"PHASE2":293,"PHASE3":295,"PHASE4":297,"NA":299},{"trials":290,"activeCount":62},[],{"trials":292,"activeCount":62},[],{"trials":294,"activeCount":62},[],{"trials":296,"activeCount":62},[],{"trials":298,"activeCount":62},[],{"trials":300,"activeCount":58,"soonestReadout":47},[301],{"nctId":45,"briefTitle":46,"status":165,"phases":302,"primaryCompletion":47,"completion":167,"start":168,"enrollment":169,"conditions":303,"interventions":304},[],[28],[48,172,173,174,175,176,177,178],{"intervention":306,"totalTrials":58,"cells":307},"intravenous crystalloid fluid, 500 mL",{"EARLY_PHASE1":308,"PHASE1":310,"PHASE2":312,"PHASE3":314,"PHASE4":316,"NA":330},{"trials":309,"activeCount":62},[],{"trials":311,"activeCount":62},[],{"trials":313,"activeCount":62},[],{"trials":315,"activeCount":62},[],{"trials":317,"activeCount":62},[318],{"nctId":319,"briefTitle":320,"status":321,"phases":322,"primaryCompletion":323,"completion":323,"start":324,"enrollment":325,"conditions":326,"interventions":329},"NCT03026777","Preventing Cardiovascular collaPse With Administration of Fluid Resuscitation Before Endotracheal Intubation","COMPLETED",[54],"2018-01","2017-01",337,[327,328],"Acute Respiratory Failure","Intubation Complication",[306],{"trials":331,"activeCount":62},[],{"intervention":333,"totalTrials":58,"cells":334},"lidocaine gel",{"EARLY_PHASE1":335,"PHASE1":337,"PHASE2":339,"PHASE3":341,"PHASE4":343,"NA":359},{"trials":336,"activeCount":62},[],{"trials":338,"activeCount":62},[],{"trials":340,"activeCount":62},[],{"trials":342,"activeCount":62},[],{"trials":344,"activeCount":62},[345],{"nctId":346,"briefTitle":347,"status":348,"phases":349,"primaryCompletion":350,"completion":350,"start":351,"enrollment":352,"conditions":353,"interventions":357},"NCT03347721","Does Lidocaine Gel Decrease Pain Perception in Women Undergoing Diagnostic Flexible Cystoscopy","UNKNOWN",[54],"2018-06-30","2016-12-01",129,[354,355,356],"Cystoscopy","Lidocaine","Pain Perception",[333,358],"Lubricant Gel",{"trials":360,"activeCount":62},[],{"intervention":358,"totalTrials":58,"cells":362},{"EARLY_PHASE1":363,"PHASE1":365,"PHASE2":367,"PHASE3":369,"PHASE4":371,"NA":377},{"trials":364,"activeCount":62},[],{"trials":366,"activeCount":62},[],{"trials":368,"activeCount":62},[],{"trials":370,"activeCount":62},[],{"trials":372,"activeCount":62},[373],{"nctId":346,"briefTitle":347,"status":348,"phases":374,"primaryCompletion":350,"completion":350,"start":351,"enrollment":352,"conditions":375,"interventions":376},[54],[354,355,356],[333,358],{"trials":378,"activeCount":62},[],{"intervention":380,"totalTrials":58,"cells":381},"dHACM",{"EARLY_PHASE1":382,"PHASE1":384,"PHASE2":386,"PHASE3":388,"PHASE4":390,"NA":402},{"trials":383,"activeCount":62},[],{"trials":385,"activeCount":62},[],{"trials":387,"activeCount":62},[],{"trials":389,"activeCount":62},[],{"trials":391,"activeCount":62},[392],{"nctId":393,"briefTitle":394,"status":348,"phases":395,"primaryCompletion":396,"completion":396,"start":397,"enrollment":398,"conditions":399,"interventions":401},"NCT04417140","A Prospective, Double-Blinded, Randomized Controlled Trial of dHACM for Incisional Hernia Prophylaxis",[54],"2022-05-20","2020-05-20",533,[400],"Incisional Hernia",[380],{"trials":403,"activeCount":62},[],{"intervention":405,"totalTrials":58,"cells":406},"Dehydrated human amnion\u002Fchorion membrane",{"EARLY_PHASE1":407,"PHASE1":409,"PHASE2":411,"PHASE3":413,"PHASE4":415,"NA":428},{"trials":408,"activeCount":62},[],{"trials":410,"activeCount":62},[],{"trials":412,"activeCount":62},[],{"trials":414,"activeCount":62},[],{"trials":416,"activeCount":62},[417],{"nctId":418,"briefTitle":419,"status":420,"phases":421,"primaryCompletion":422,"completion":422,"start":423,"enrollment":424,"conditions":425,"interventions":427},"NCT05120726","A Novel Therapeutic Treatment of Pyoderma Gangrenosum","TERMINATED",[54],"2024-11-18","2021-06-02",5,[426],"Pyoderma Gangrenosum",[405],{"trials":429,"activeCount":62},[],{"intervention":431,"totalTrials":58,"cells":432},"tetracaine HCl and oxymetazoline HCL",{"EARLY_PHASE1":433,"PHASE1":435,"PHASE2":437,"PHASE3":439,"PHASE4":441,"NA":458},{"trials":434,"activeCount":62},[],{"trials":436,"activeCount":62},[],{"trials":438,"activeCount":62},[],{"trials":440,"activeCount":62},[],{"trials":442,"activeCount":62},[443],{"nctId":444,"briefTitle":445,"status":348,"phases":446,"primaryCompletion":350,"completion":350,"start":447,"enrollment":448,"conditions":449,"interventions":453},"NCT03368391",": Pulpal Blood Flow With the Use of Intra-nasal Anesthetic",[54],"2018-01-03",25,[450,451,452],"Local Anesthetic Drug Adverse Reaction","Local Infiltration","Pulp Disease, Dental",[431,454,455,456,457],"2% Lidocaine with 1:100,000 epinephrine","3% Mepivacaine with 1:100,000 epinephrine","saline intranasal","saline infiltration",{"trials":459,"activeCount":62},[],{"intervention":455,"totalTrials":58,"cells":461},{"EARLY_PHASE1":462,"PHASE1":464,"PHASE2":466,"PHASE3":468,"PHASE4":470,"NA":476},{"trials":463,"activeCount":62},[],{"trials":465,"activeCount":62},[],{"trials":467,"activeCount":62},[],{"trials":469,"activeCount":62},[],{"trials":471,"activeCount":62},[472],{"nctId":444,"briefTitle":445,"status":348,"phases":473,"primaryCompletion":350,"completion":350,"start":447,"enrollment":448,"conditions":474,"interventions":475},[54],[450,451,452],[431,454,455,456,457],{"trials":477,"activeCount":62},[],{"intervention":456,"totalTrials":58,"cells":479},{"EARLY_PHASE1":480,"PHASE1":482,"PHASE2":484,"PHASE3":486,"PHASE4":488,"NA":494},{"trials":481,"activeCount":62},[],{"trials":483,"activeCount":62},[],{"trials":485,"activeCount":62},[],{"trials":487,"activeCount":62},[],{"trials":489,"activeCount":62},[490],{"nctId":444,"briefTitle":445,"status":348,"phases":491,"primaryCompletion":350,"completion":350,"start":447,"enrollment":448,"conditions":492,"interventions":493},[54],[450,451,452],[431,454,455,456,457],{"trials":495,"activeCount":62},[],{"intervention":457,"totalTrials":58,"cells":497},{"EARLY_PHASE1":498,"PHASE1":500,"PHASE2":502,"PHASE3":504,"PHASE4":506,"NA":512},{"trials":499,"activeCount":62},[],{"trials":501,"activeCount":62},[],{"trials":503,"activeCount":62},[],{"trials":505,"activeCount":62},[],{"trials":507,"activeCount":62},[508],{"nctId":444,"briefTitle":445,"status":348,"phases":509,"primaryCompletion":350,"completion":350,"start":447,"enrollment":448,"conditions":510,"interventions":511},[54],[450,451,452],[431,454,455,456,457],{"trials":513,"activeCount":62},[],{"intervention":515,"totalTrials":58,"cells":516},"PEG-Intron Plus REBETOL",{"EARLY_PHASE1":517,"PHASE1":519,"PHASE2":521,"PHASE3":523,"PHASE4":525,"NA":537},{"trials":518,"activeCount":62},[],{"trials":520,"activeCount":62},[],{"trials":522,"activeCount":62},[],{"trials":524,"activeCount":62},[],{"trials":526,"activeCount":62},[527],{"nctId":528,"briefTitle":529,"status":321,"phases":530,"primaryCompletion":531,"completion":531,"start":532,"enrollment":533,"conditions":534,"interventions":536},"NCT00351871","Influence of Marker of Insulin Resistance Upon Hepatitis C Virus (HCV) Treatment Responses to PEG Intron and Rebetol Therapy",[54],"2007-11","2002-04",400,[535],"Chronic Hepatitis C",[515],{"trials":538,"activeCount":62},[],{"intervention":540,"totalTrials":58,"cells":541},"Hydroxychloroquine",{"EARLY_PHASE1":542,"PHASE1":544,"PHASE2":546,"PHASE3":548,"PHASE4":566,"NA":568},{"trials":543,"activeCount":62},[],{"trials":545,"activeCount":62},[],{"trials":547,"activeCount":62},[],{"trials":549,"activeCount":62},[550],{"nctId":551,"briefTitle":552,"status":348,"phases":553,"primaryCompletion":554,"completion":555,"start":556,"enrollment":557,"conditions":558,"interventions":565},"NCT04363450","Hydroxychloroquine as Prophylaxis for COVID-19 in Healthcare Workers (HCQPreP)",[53],"2021-03-31","2021-06-01","2020-04-27",1700,[559,560,561,562,563,564,540],"COVID-19","Corona Virus Infection","Wuhan Coronavirus","Prophylaxis","Healthcare Worker","Sars-CoV2",[540],{"trials":567,"activeCount":62},[],{"trials":569,"activeCount":62},[],{"intervention":571,"totalTrials":58,"cells":572},"Hyperbaric Oxygen",{"EARLY_PHASE1":573,"PHASE1":575,"PHASE2":577,"PHASE3":579,"PHASE4":594,"NA":596},{"trials":574,"activeCount":62},[],{"trials":576,"activeCount":62},[],{"trials":578,"activeCount":62},[],{"trials":580,"activeCount":62},[581],{"nctId":582,"briefTitle":583,"status":348,"phases":584,"primaryCompletion":585,"completion":586,"start":587,"enrollment":588,"conditions":589,"interventions":592},"NCT02089594","Hyperbaric Oxygen Treatment to Treat Mild Traumatic Brain Injury (mTBI)\u002FPersistent Post-Concussion Syndrome (PPCS)",[53],"2018-03","2019-03","2014-05",59,[590,591],"Post-Concussion Syndrome","Traumatic Brain Injury",[571,593],"No Hyperbaric Oxygen",{"trials":595,"activeCount":62},[],{"trials":597,"activeCount":62},[],{"intervention":593,"totalTrials":58,"cells":599},{"EARLY_PHASE1":600,"PHASE1":602,"PHASE2":604,"PHASE3":606,"PHASE4":612,"NA":614},{"trials":601,"activeCount":62},[],{"trials":603,"activeCount":62},[],{"trials":605,"activeCount":62},[],{"trials":607,"activeCount":62},[608],{"nctId":582,"briefTitle":583,"status":348,"phases":609,"primaryCompletion":585,"completion":586,"start":587,"enrollment":588,"conditions":610,"interventions":611},[53],[590,591],[571,593],{"trials":613,"activeCount":62},[],{"trials":615,"activeCount":62},[],{"intervention":617,"totalTrials":58,"cells":618},"MMR vaccine",{"EARLY_PHASE1":619,"PHASE1":621,"PHASE2":623,"PHASE3":625,"PHASE4":637,"NA":639},{"trials":620,"activeCount":62},[],{"trials":622,"activeCount":62},[],{"trials":624,"activeCount":62},[],{"trials":626,"activeCount":62},[627],{"nctId":628,"briefTitle":629,"status":321,"phases":630,"primaryCompletion":631,"completion":631,"start":632,"enrollment":633,"conditions":634,"interventions":636},"NCT04475081","Use of a Live Attenuated Vaccine as an Immune-based Preventive Against COVID-19-associated Sepsis",[53],"2022-05-15","2020-09-22",50,[635],"Sepsis Syndrome",[617],{"trials":638,"activeCount":62},[],{"trials":640,"activeCount":62},[],{"intervention":642,"totalTrials":58,"cells":643},"Tranexamic Acid (TXA) treatment",{"EARLY_PHASE1":644,"PHASE1":646,"PHASE2":648,"PHASE3":650,"PHASE4":665,"NA":667},{"trials":645,"activeCount":62},[],{"trials":647,"activeCount":62},[],{"trials":649,"activeCount":62},[],{"trials":651,"activeCount":62},[652],{"nctId":653,"briefTitle":654,"status":321,"phases":655,"primaryCompletion":656,"completion":657,"start":658,"enrollment":659,"conditions":660,"interventions":664},"NCT07125508","Tranexamic Acid for The Management of Bleeding Gastrointestinal Angioectasias",[52,53],"2024-09-01","2024-12-15","2023-08-01",40,[661,662,663],"Anemia","Small Bowel Bleeding","Angioectasias",[642],{"trials":666,"activeCount":62},[],{"trials":668,"activeCount":62},[],{"intervention":670,"totalTrials":24,"cells":671},"Polyphenon E",{"EARLY_PHASE1":672,"PHASE1":674,"PHASE2":685,"PHASE3":695,"PHASE4":697,"NA":699},{"trials":673,"activeCount":62},[],{"trials":675,"activeCount":62},[676],{"nctId":677,"briefTitle":678,"status":321,"phases":679,"primaryCompletion":680,"completion":680,"start":681,"enrollment":682,"conditions":683,"interventions":684},"NCT00836719","Safety of Polyphenon E in Multiple Sclerosis Pilot Study",[51],"2010-11","2009-02",10,[20],[670],{"trials":686,"activeCount":62},[687],{"nctId":688,"briefTitle":689,"status":420,"phases":690,"primaryCompletion":691,"completion":691,"start":692,"enrollment":8,"conditions":693,"interventions":694},"NCT01451723","Safety and Neuroprotective Effects of Polyphenon E in MS; Phase II",[52],"2013-02","2011-07",[20],[670],{"trials":696,"activeCount":62},[],{"trials":698,"activeCount":62},[],{"trials":700,"activeCount":62},[],{"intervention":702,"totalTrials":58,"cells":703},"Branch Chain Amino Acid",{"EARLY_PHASE1":704,"PHASE1":706,"PHASE2":708,"PHASE3":721,"PHASE4":723,"NA":725},{"trials":705,"activeCount":62},[],{"trials":707,"activeCount":62},[],{"trials":709,"activeCount":62},[710],{"nctId":711,"briefTitle":712,"status":713,"phases":714,"primaryCompletion":37,"completion":715,"start":555,"enrollment":62,"conditions":716,"interventions":720},"NCT03908255","Branched-chain Amino Acid Supplementation for Hepatocellular Carcinoma","WITHDRAWN",[52],"2023-12-30",[717,718,719],"Hepatocellular Carcinoma","Cirrhosis","Liver Failure",[702],{"trials":722,"activeCount":62},[],{"trials":724,"activeCount":62},[],{"trials":726,"activeCount":62},[],{"intervention":728,"totalTrials":58,"cells":729},"95% Pure ECGC capsules 200mg",{"EARLY_PHASE1":730,"PHASE1":732,"PHASE2":734,"PHASE3":745,"PHASE4":747,"NA":749},{"trials":731,"activeCount":62},[],{"trials":733,"activeCount":62},[],{"trials":735,"activeCount":62},[736],{"nctId":737,"briefTitle":738,"status":713,"phases":739,"primaryCompletion":740,"completion":741,"start":742,"enrollment":62,"conditions":743,"interventions":744},"NCT02011451","Safety and Brain Protection Effects of the Green Tea Extract Theaphenon 95% (95% Pure EGCG) in Multiple Sclerosis",[52],"2017-03","2017-12","2015-12",[20],[728],{"trials":746,"activeCount":62},[],{"trials":748,"activeCount":62},[],{"trials":750,"activeCount":62},[],{"intervention":752,"totalTrials":58,"cells":753},"vatalanib",{"EARLY_PHASE1":754,"PHASE1":756,"PHASE2":758,"PHASE3":771,"PHASE4":773,"NA":775},{"trials":755,"activeCount":62},[],{"trials":757,"activeCount":62},[],{"trials":759,"activeCount":62},[760],{"nctId":761,"briefTitle":762,"status":321,"phases":763,"primaryCompletion":764,"completion":765,"start":766,"enrollment":767,"conditions":768,"interventions":770},"NCT00590343","Safety and Efficacy Study of PTK787\u002FZK222584 to Treat Metastatic Neuroendocrine Tumors",[52],"2010-03","2010-10","2004-11",23,[769],"Metastatic Neuroendocrine Tumors",[752],{"trials":772,"activeCount":62},[],{"trials":774,"activeCount":62},[],{"trials":776,"activeCount":62},[],{"intervention":778,"totalTrials":58,"cells":779},"Aspirin 81 mg",{"EARLY_PHASE1":780,"PHASE1":782,"PHASE2":784,"PHASE3":798,"PHASE4":800,"NA":802},{"trials":781,"activeCount":62},[],{"trials":783,"activeCount":62},[],{"trials":785,"activeCount":62},[786],{"nctId":787,"briefTitle":788,"status":713,"phases":789,"primaryCompletion":790,"completion":790,"start":791,"enrollment":62,"conditions":792,"interventions":797},"NCT04363840","The LEAD COVID-19 Trial: Low-risk, Early Aspirin and Vitamin D to Reduce COVID-19 Hospitalizations",[52],"2020-12","2020-05",[793,794,795,796],"COVID","Vitamin D Deficiency","Coagulopathy","Disseminated Intravascular Coagulation",[778],{"trials":799,"activeCount":62},[],{"trials":801,"activeCount":62},[],{"trials":803,"activeCount":62},[],{"intervention":805,"totalTrials":58,"cells":806},"Influenza vaccination",{"EARLY_PHASE1":807,"PHASE1":809,"PHASE2":811,"PHASE3":824,"PHASE4":826,"NA":828},{"trials":808,"activeCount":62},[],{"trials":810,"activeCount":62},[],{"trials":812,"activeCount":62},[813],{"nctId":814,"briefTitle":815,"status":348,"phases":816,"completion":817,"start":818,"conditions":819,"interventions":822},"NCT00380679","Offering Influenza and Pneumococcal Vaccine to Patients Being Evaluated in the Emergency Department",[52],"2006-03","2005-12",[820,821],"High Risk for Serious Influenza","High Risk for Pneumonia",[805,823],"Pneumococcal polysaccharide vaccination",{"trials":825,"activeCount":62},[],{"trials":827,"activeCount":62},[],{"trials":829,"activeCount":62},[],{"intervention":823,"totalTrials":58,"cells":831},{"EARLY_PHASE1":832,"PHASE1":834,"PHASE2":836,"PHASE3":842,"PHASE4":844,"NA":846},{"trials":833,"activeCount":62},[],{"trials":835,"activeCount":62},[],{"trials":837,"activeCount":62},[838],{"nctId":814,"briefTitle":815,"status":348,"phases":839,"completion":817,"start":818,"conditions":840,"interventions":841},[52],[820,821],[805,823],{"trials":843,"activeCount":62},[],{"trials":845,"activeCount":62},[],{"trials":847,"activeCount":62},[],{"intervention":849,"totalTrials":58,"cells":850},"ASA",{"EARLY_PHASE1":851,"PHASE1":853,"PHASE2":855,"PHASE3":867,"PHASE4":869,"NA":871},{"trials":852,"activeCount":62},[],{"trials":854,"activeCount":62},[],{"trials":856,"activeCount":62},[857],{"nctId":858,"briefTitle":859,"status":348,"phases":860,"primaryCompletion":861,"completion":861,"start":862,"enrollment":863,"conditions":864,"interventions":866},"NCT04937088","Outpatient Liquid Aspirin (OLA)",[52],"2022-12-05","2021-12-06",200,[865],"Covid19",[849],{"trials":868,"activeCount":62},[],{"trials":870,"activeCount":62},[],{"trials":872,"activeCount":62},[],{"intervention":874,"totalTrials":58,"cells":875},"Inhaled iloprost 5.0 mcg",{"EARLY_PHASE1":876,"PHASE1":878,"PHASE2":880,"PHASE3":892,"PHASE4":894,"NA":896},{"trials":877,"activeCount":62},[],{"trials":879,"activeCount":62},[],{"trials":881,"activeCount":62},[882],{"nctId":883,"briefTitle":884,"status":321,"phases":885,"primaryCompletion":886,"completion":886,"start":887,"enrollment":888,"conditions":889,"interventions":891},"NCT01941225","Inhaled Iloprost, Dynamic Hyperinflation, and Oxidative Stress in COPD Patients",[52],"2016-11","2013-09",24,[890],"Chronic Obstructive Pulmonary Disease",[874],{"trials":893,"activeCount":62},[],{"trials":895,"activeCount":62},[],{"trials":897,"activeCount":62},[],{"intervention":899,"totalTrials":58,"cells":900},"methylprednisolone sodium succinate",{"EARLY_PHASE1":901,"PHASE1":903,"PHASE2":905,"PHASE3":917,"PHASE4":919,"NA":921},{"trials":902,"activeCount":62},[],{"trials":904,"activeCount":62},[],{"trials":906,"activeCount":62},[907],{"nctId":908,"briefTitle":909,"status":348,"phases":910,"primaryCompletion":911,"completion":911,"start":912,"enrollment":682,"conditions":913,"interventions":916},"NCT04219995","Pilot Trial to Evaluate The Effect of Oral Methylprednisolone on Seizure Frequency in Children With Epilepsy",[51,52],"2021-02","2020-02-03",[914,915],"Intractable Epilepsy","Convulsive Seizures",[899],{"trials":918,"activeCount":62},[],{"trials":920,"activeCount":62},[],{"trials":922,"activeCount":62},[],{"intervention":924,"totalTrials":58,"cells":925},"Methylene blue",{"EARLY_PHASE1":926,"PHASE1":928,"PHASE2":930,"PHASE3":941,"PHASE4":943,"NA":945},{"trials":927,"activeCount":62},[],{"trials":929,"activeCount":62},[],{"trials":931,"activeCount":62},[932],{"nctId":933,"briefTitle":934,"status":321,"phases":935,"primaryCompletion":936,"completion":936,"start":766,"enrollment":937,"conditions":938,"interventions":940},"NCT00784849","Feasibility of One-Step Sentinel Lymph Node (SLN) Biopsy With Radiolabeled Methylene Blue (IND 70,627)",[52],"2011-06",62,[939],"Breast Cancer",[924],{"trials":942,"activeCount":62},[],{"trials":944,"activeCount":62},[],{"trials":946,"activeCount":62},[],{"intervention":948,"totalTrials":58,"cells":949},"PA-1-STK ovarian carcinoma vaccine",{"EARLY_PHASE1":950,"PHASE1":952,"PHASE2":963,"PHASE3":965,"PHASE4":967,"NA":969},{"trials":951,"activeCount":62},[],{"trials":953,"activeCount":62},[954],{"nctId":955,"briefTitle":956,"status":348,"phases":957,"start":958,"conditions":959,"interventions":961},"NCT00006216","Vaccine Therapy and Ganciclovir in Treating Patients With Mesothelioma",[51],"1997-08",[960],"Malignant Mesothelioma",[948,962],"ganciclovir",{"trials":964,"activeCount":62},[],{"trials":966,"activeCount":62},[],{"trials":968,"activeCount":62},[],{"trials":970,"activeCount":62},[],{"intervention":962,"totalTrials":58,"cells":972},{"EARLY_PHASE1":973,"PHASE1":975,"PHASE2":981,"PHASE3":983,"PHASE4":985,"NA":987},{"trials":974,"activeCount":62},[],{"trials":976,"activeCount":62},[977],{"nctId":955,"briefTitle":956,"status":348,"phases":978,"start":958,"conditions":979,"interventions":980},[51],[960],[948,962],{"trials":982,"activeCount":62},[],{"trials":984,"activeCount":62},[],{"trials":986,"activeCount":62},[],{"trials":988,"activeCount":62},[],{"intervention":990,"totalTrials":58,"cells":991},"Local Anesthesia",{"EARLY_PHASE1":992,"PHASE1":1006,"PHASE2":1008,"PHASE3":1010,"PHASE4":1012,"NA":1014},{"trials":993,"activeCount":62},[994],{"nctId":995,"briefTitle":996,"status":321,"phases":997,"primaryCompletion":998,"completion":999,"start":1000,"enrollment":1001,"conditions":1002,"interventions":1004},"NCT06874244","Clinical Evaluation of no Needle Dental Anesthesia Compared to Syringe Anesthesia Delivery",[50],"2025-06-12","2025-07-01","2024-08-01",20,[1003],"Local Anesthesia Injection Pain",[990,1005],"Iontophoresis of Tetracaine and oxymetazoline",{"trials":1007,"activeCount":62},[],{"trials":1009,"activeCount":62},[],{"trials":1011,"activeCount":62},[],{"trials":1013,"activeCount":62},[],{"trials":1015,"activeCount":62},[],{"intervention":1005,"totalTrials":58,"cells":1017},{"EARLY_PHASE1":1018,"PHASE1":1024,"PHASE2":1026,"PHASE3":1028,"PHASE4":1030,"NA":1032},{"trials":1019,"activeCount":62},[1020],{"nctId":995,"briefTitle":996,"status":321,"phases":1021,"primaryCompletion":998,"completion":999,"start":1000,"enrollment":1001,"conditions":1022,"interventions":1023},[50],[1003],[990,1005],{"trials":1025,"activeCount":62},[],{"trials":1027,"activeCount":62},[],{"trials":1029,"activeCount":62},[],{"trials":1031,"activeCount":62},[],{"trials":1033,"activeCount":62},[],{"intervention":454,"totalTrials":24,"cells":1035},{"EARLY_PHASE1":1036,"PHASE1":1038,"PHASE2":1040,"PHASE3":1042,"PHASE4":1044,"NA":1050},{"trials":1037,"activeCount":62},[],{"trials":1039,"activeCount":62},[],{"trials":1041,"activeCount":62},[],{"trials":1043,"activeCount":62},[],{"trials":1045,"activeCount":62},[1046],{"nctId":444,"briefTitle":445,"status":348,"phases":1047,"primaryCompletion":350,"completion":350,"start":447,"enrollment":448,"conditions":1048,"interventions":1049},[54],[450,451,452],[431,454,455,456,457],{"trials":1051,"activeCount":62},[1052],{"nctId":1053,"briefTitle":1054,"status":321,"phases":1055,"primaryCompletion":1056,"completion":1056,"start":1057,"enrollment":24,"conditions":1058,"interventions":1061},"NCT05406895","Use of CBCT to Improve Inferior Alveolar Nerve Block Success",[55],"2024-03-30","2022-05-25",[1059,1060],"Inferior Alveolar Nerve","Mandibular Nerve Blocks",[454],{"intervention":1063,"totalTrials":58,"cells":1064},"Thalidomide",{"EARLY_PHASE1":1065,"PHASE1":1067,"PHASE2":1069,"PHASE3":1071,"PHASE4":1073,"NA":1075},{"trials":1066,"activeCount":62},[],{"trials":1068,"activeCount":62},[],{"trials":1070,"activeCount":62},[],{"trials":1072,"activeCount":62},[],{"trials":1074,"activeCount":62},[],{"trials":1076,"activeCount":62},[1077],{"nctId":1078,"briefTitle":1079,"status":321,"phases":1080,"enrollment":1001,"conditions":1081,"interventions":1083},"NCT00002174","Further Evaluation of Thalidomide's Ability to Potentiate the Immune Response to HIV-Infected Patients",[55],[1082],"HIV Infections",[1063],{"intervention":1085,"totalTrials":58,"cells":1086},"lamotrigine",{"EARLY_PHASE1":1087,"PHASE1":1089,"PHASE2":1091,"PHASE3":1093,"PHASE4":1095,"NA":1097},{"trials":1088,"activeCount":62},[],{"trials":1090,"activeCount":62},[],{"trials":1092,"activeCount":62},[],{"trials":1094,"activeCount":62},[],{"trials":1096,"activeCount":62},[],{"trials":1098,"activeCount":62},[1099],{"nctId":1100,"briefTitle":1101,"status":321,"phases":1102,"primaryCompletion":1103,"completion":1104,"start":1105,"enrollment":1106,"conditions":1107,"interventions":1109},"NCT00901407","Lamotrigine Augmentation in Resistant Depression",[55],"2006-07","2007-04","2003-12",138,[1108],"Unipolar Depression",[1085,1110],"paroxetine",{"intervention":1110,"totalTrials":58,"cells":1112},{"EARLY_PHASE1":1113,"PHASE1":1115,"PHASE2":1117,"PHASE3":1119,"PHASE4":1121,"NA":1123},{"trials":1114,"activeCount":62},[],{"trials":1116,"activeCount":62},[],{"trials":1118,"activeCount":62},[],{"trials":1120,"activeCount":62},[],{"trials":1122,"activeCount":62},[],{"trials":1124,"activeCount":62},[1125],{"nctId":1100,"briefTitle":1101,"status":321,"phases":1126,"primaryCompletion":1103,"completion":1104,"start":1105,"enrollment":1106,"conditions":1127,"interventions":1128},[55],[1108],[1085,1110]]